CD5 and T-cell acute lymphoblastic leukemia: Targeting CD5 via CART is promising, as seen in the MAGENTA study and recent Phase I studies of donor-derived CD5 CAR T-cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia [44,45].